ArticleJournal of medical ethics2020
Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.
Article in Journal of medical ethics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- YouTube and Religion during COVID-19: Analyzing Indonesian Islamic Groups' Narratives.Journal of religion and health · 2026Article
- Exploring the ethics of tuberculosis human challenge models.Journal of medical ethics · 2026Article
- Do coronavirus vaccine challenge trials have a distinctive generalisability problem?Journal of medical ethics · 2022Article
- Pandemic vaccine testing: Combining conventional and challenge studies.Pharmacoepidemiology and drug safety · 2022Article
- How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Review
- Article
- Reply to Hasford and to Spinola et al.The Journal of infectious diseases · 2020Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or 'challenge') trials. These trials would involve the deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend this proposal against the charge that there is still too much uncertainty surrounding the risks of COVID-19 to responsibly run such a trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.